Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
John K. Botson, Kenneth G. Saag, Jeff Peterson, et al.
Arthritis & Rheumatology (2022) Vol. 75, Iss. 2, pp. 293-304
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

M2 Macrophage Hybrid Membrane‐Camouflaged Targeted Biomimetic Nanosomes to Reprogram Inflammatory Microenvironment for Enhanced Enzyme‐Thermo‐Immunotherapy
Ran Chen, Jie Yang, Mingjun Wu, et al.
Advanced Materials (2023) Vol. 35, Iss. 39
Open Access | Times Cited: 55
Mechanisms and rationale for uricase use in patients with gout
Naomi Schlesinger, Fernando Perez‐Ruiz, Frédéric Lioté
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 10, pp. 640-649
Closed Access | Times Cited: 46
Macrophage membrane-camouflaged biomimetic nanovesicles for targeted treatment of arthritis
Xin Huang, Weiyue Zhang
Ageing Research Reviews (2024) Vol. 95, pp. 102241-102241
Open Access | Times Cited: 13
Controversies and practical management of patients with gout and chronic kidney disease
Richard J. Johnson, Brian F. Mandell, Naomi Schlesinger, et al.
Kidney International (2024) Vol. 106, Iss. 4, pp. 573-582
Closed Access | Times Cited: 13
A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
John K. Botson, Kenneth G. Saag, Jeff Peterson, et al.
ACR Open Rheumatology (2023) Vol. 5, Iss. 8, pp. 407-418
Open Access | Times Cited: 14
The impact of the human gut microbiome on the treatment of autoimmune disease
Renuka R. Nayak, Diego Orellana
Immunological Reviews (2024) Vol. 325, Iss. 1, pp. 107-130
Open Access | Times Cited: 4
Escherichia coli in the production of biopharmaceuticals
İbrahim İncir, Özlem Kaplan
Biotechnology and Applied Biochemistry (2024)
Open Access | Times Cited: 4
Pegloticase and Methotrexate Cotherapy in Patients With Uncontrolled Gout With Prior Pegloticase Monotherapy Failure: Findings of an Open‐Label Trial
O. Troum, John K. Botson, K. Obermeyer, et al.
ACR Open Rheumatology (2025) Vol. 7, Iss. 1
Open Access
Gout
John FitzGerald
Annals of Internal Medicine (2025)
Closed Access
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout
Herbert S. B. Baraf, Puja Khanna, Alan Kivitz, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 4, pp. 1058-1067
Open Access | Times Cited: 9
Critical appraisal of serum urate targets in the management of gout
Lisa K. Stamp, Nicola Dalbeth
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 10, pp. 603-609
Closed Access | Times Cited: 14
Emerging therapeutic options for refractory gout
Kanon Jatuworapruk, Worawit Louthrenoo
Nature Reviews Rheumatology (2023) Vol. 20, Iss. 2, pp. 73-74
Closed Access | Times Cited: 5
Examination of monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: exploratory dual-energy computed tomography findings from MIRROR RCT
Nicola Dalbeth, John K. Botson, Kenneth G. Saag, et al.
Joint Bone Spine (2024) Vol. 91, Iss. 4, pp. 105715-105715
Open Access | Times Cited: 1
Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series
John A. Albert, Aaron Broadwell, Lissa Padnick‐Silver, et al.
Medicine (2024) Vol. 103, Iss. 10, pp. e37424-e37424
Open Access | Times Cited: 1
Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study
Joshua Card-Gowers, Lise Retat, Ada Kumar, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 4, pp. 913-926
Open Access | Times Cited: 1
Safety and efficacy of gout treatments in people with renal impairment
Hamish Farquhar, Angelo Gaffo, Lisa K. Stamp
Exploration of Musculoskeletal Diseases (2024) Vol. 2, Iss. 5, pp. 360-374
Open Access | Times Cited: 1
Exploration of uricase-like activity in Pd@Ir nanosheets and their application in relieving acute gout using self-cascade reaction
Zichen Ye, Yayao Wang, Zhang Gong-xin, et al.
Journal of Colloid and Interface Science (2024) Vol. 678, pp. 380-392
Closed Access | Times Cited: 1
The Therapeutic Management of Chemical and Herbal Medications on Uric Acid Levels and Gout: Modern and Traditional Wisdom
Zhijian Lin, Jeetendra Kumar Gupta, Mohsin Maqbool, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 11, pp. 1507-1507
Open Access | Times Cited: 1
Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice
Lily Tran, Soumen Das, Liangjun Zhao, et al.
Biomacromolecules (2023) Vol. 24, Iss. 5, pp. 2003-2008
Open Access | Times Cited: 3
The Singapore Experience With Uncontrolled Gout: Unmet Needs in the Management of Patients
Zheng Cong Lee, Anindita Santosa, Andrew Yu Keat Khor, et al.
Cureus (2023)
Open Access | Times Cited: 2
PEGylated porcine–human recombinant uricase: A novel fusion protein with improved efficacy and safety for the treatment of hyperuricemia and renal complications
Xiangyan Wang, Hao Lu, Jun Rong, et al.
Open Life Sciences (2024) Vol. 19, Iss. 1
Open Access
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Emily E. Holladay, Amy S. Mudano, Fenglong Xie, et al.
Arthritis Research & Therapy (2024) Vol. 26, Iss. 1
Open Access
Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy
Emily E. Holladay, Amy S. Mudano, Fenglong Xie, et al.
Arthritis Care & Research (2024) Vol. 76, Iss. 10, pp. 1361-1370
Open Access
Year in Review 2023: Gout Clinical Research
Gregory J. Challener, Chio Yokose
Gout Urate and Crystal Deposition Disease (2024) Vol. 2, Iss. 4, pp. 354-369
Open Access
Research hotspots and trends related to pain in gouty arthritis from 2014 to 2024: A bibliometric analysis
Chengyin Lu, Yuxing Guo, Zhiqiang Luo, et al.
Medicine (2024) Vol. 103, Iss. 46, pp. e40525-e40525
Open Access
Page 1 - Next Page

Scroll to top